<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 03 Mar 2021 07:54:34 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>强生腺病毒载体新冠疫苗FDA申报紧急上市答辩PPT</title><link>https://mp.weixin.qq.com/s/ziAhHp7r4Ts5O9a3RoRwDg</link><description></description><content:encoded><![CDATA[强生腺病毒载体新冠疫苗FDA申报紧急上市答辩PPT]]></content:encoded><pubDate>Tue, 02 Mar 2021 19:24:49 +0800</pubDate></item><item><title>NMPA综合司再次公开征求《疫苗生产流通管理规定（征求意见稿）》意见</title><link>https://mp.weixin.qq.com/s/Fl82giLVN0vPO6p-uucdZg</link><description></description><content:encoded><![CDATA[NMPA综合司再次公开征求《疫苗生产流通管理规定（征求意见稿）》意见]]></content:encoded><pubDate>Tue, 02 Mar 2021 19:24:49 +0800</pubDate></item><item><title>某药监局发布《药品生产监督检查缺陷整改指南》！</title><link>https://mp.weixin.qq.com/s/Mv6GZ8UhBp1Pp_6RGcZEjQ</link><description></description><content:encoded><![CDATA[某药监局发布《药品生产监督检查缺陷整改指南》！]]></content:encoded><pubDate>Tue, 02 Mar 2021 19:24:49 +0800</pubDate></item><item><title>李宾讲临床丨方案设计与风险规避</title><link>https://mp.weixin.qq.com/s/md2rBzwTDSMyqQ2pHWOeOg</link><description></description><content:encoded><![CDATA[李宾讲临床丨方案设计与风险规避]]></content:encoded><pubDate>Tue, 02 Mar 2021 19:24:49 +0800</pubDate></item><item><title>药物杂质遗传毒性评价策略与监管研究</title><link>https://mp.weixin.qq.com/s/Hv-kqKBTNJgkjNLxkksHAw</link><description></description><content:encoded><![CDATA[药物杂质遗传毒性评价策略与监管研究]]></content:encoded><pubDate>Mon, 01 Mar 2021 19:19:06 +0800</pubDate></item><item><title>AASLD会议共识：肝细胞癌的临床试验设计和终点</title><link>https://mp.weixin.qq.com/s/lAMykrPxa4ekekk8O4biZw</link><description></description><content:encoded><![CDATA[AASLD会议共识：肝细胞癌的临床试验设计和终点]]></content:encoded><pubDate>Mon, 01 Mar 2021 19:19:06 +0800</pubDate></item><item><title>《生物制品批签发管理办法》今日实施</title><link>https://mp.weixin.qq.com/s/M0AKbgkv4Wu0Aa9SS2kPDQ</link><description></description><content:encoded><![CDATA[《生物制品批签发管理办法》今日实施]]></content:encoded><pubDate>Mon, 01 Mar 2021 19:19:06 +0800</pubDate></item><item><title>如何解读ICH指导原则中的杂质三限（报告限，鉴定限，界定限）</title><link>https://mp.weixin.qq.com/s/4OsbzIFv4c_jzOn4KH8uSQ</link><description></description><content:encoded><![CDATA[如何解读ICH指导原则中的杂质三限（报告限，鉴定限，界定限）]]></content:encoded><pubDate>Sun, 28 Feb 2021 18:56:01 +0800</pubDate></item><item><title>提高双特异性抗体生产和质量的策略</title><link>https://mp.weixin.qq.com/s/93nhV2kDadn3i2K1TRcTGw</link><description></description><content:encoded><![CDATA[提高双特异性抗体生产和质量的策略]]></content:encoded><pubDate>Sun, 28 Feb 2021 18:56:01 +0800</pubDate></item><item><title>注射剂一致性评价的全流程药学要求</title><link>https://mp.weixin.qq.com/s/Arquc59z-ByV53EnfP3wnQ</link><description></description><content:encoded><![CDATA[注射剂一致性评价的全流程药学要求]]></content:encoded><pubDate>Sun, 28 Feb 2021 18:56:01 +0800</pubDate></item><item><title>Nat Rev| 抗体偶联药物ADC从理念到临床</title><link>https://mp.weixin.qq.com/s/uz-jsMPmYxx7OFo2ZDJKoQ</link><description></description><content:encoded><![CDATA[Nat Rev| 抗体偶联药物ADC从理念到临床]]></content:encoded><pubDate>Sun, 28 Feb 2021 18:56:01 +0800</pubDate></item><item><title>《药品注册管理办法》48个热点问题答疑</title><link>https://mp.weixin.qq.com/s/y-bCRSWwQkzVABdHpKE6bA</link><description></description><content:encoded><![CDATA[《药品注册管理办法》48个热点问题答疑]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:00:47 +0800</pubDate></item><item><title>科学家研制超级“NK细胞”，更强的活性，抵御外来细胞</title><link>https://mp.weixin.qq.com/s/RjvlnxE6tymJHGgm-1JbiQ</link><description></description><content:encoded><![CDATA[科学家研制超级“NK细胞”，更强的活性，抵御外来细胞]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:00:47 +0800</pubDate></item><item><title>NMPA I 批准注册117个医疗器械产品的公告（2021年1月）（2021年 第26号）</title><link>https://mp.weixin.qq.com/s/88ppsC-xukLZKzX7OagyQA</link><description></description><content:encoded><![CDATA[NMPA I 批准注册117个医疗器械产品的公告（2021年1月）（2021年 第26号）]]></content:encoded><pubDate>Sat, 27 Feb 2021 23:00:47 +0800</pubDate></item><item><title>【CDE文章】多规格口服固体制剂仿制药生物豁免的药学考虑</title><link>https://mp.weixin.qq.com/s/uEqq_OfiYFjSHOpuznIZuA</link><description></description><content:encoded><![CDATA[【CDE文章】多规格口服固体制剂仿制药生物豁免的药学考虑]]></content:encoded><pubDate>Fri, 26 Feb 2021 23:13:28 +0800</pubDate></item><item><title>【周立春】工艺变更申报与注册工艺核查的政策解读</title><link>https://mp.weixin.qq.com/s/qm8U8alrczQhBwC24VDYkQ</link><description></description><content:encoded><![CDATA[【周立春】工艺变更申报与注册工艺核查的政策解读]]></content:encoded><pubDate>Fri, 26 Feb 2021 23:13:28 +0800</pubDate></item><item><title>【百科】“漫说”干细胞神奇在哪里？</title><link>https://mp.weixin.qq.com/s/esTrtlI9CSgs_AbmYtB-AA</link><description></description><content:encoded><![CDATA[【百科】“漫说”干细胞神奇在哪里？]]></content:encoded><pubDate>Fri, 26 Feb 2021 23:13:28 +0800</pubDate></item><item><title>双抗时代，渐入佳境</title><link>https://mp.weixin.qq.com/s/AP_dayjSy7__2INy-CFiMQ</link><description></description><content:encoded><![CDATA[双抗时代，渐入佳境]]></content:encoded><pubDate>Thu, 25 Feb 2021 20:17:46 +0800</pubDate></item><item><title>免疫NK细胞是抗癌的主力军</title><link>https://mp.weixin.qq.com/s/TCurRZfxyOF6QKlUZCOhLw</link><description></description><content:encoded><![CDATA[免疫NK细胞是抗癌的主力军]]></content:encoded><pubDate>Thu, 25 Feb 2021 20:17:46 +0800</pubDate></item><item><title>【速递】CDE发布《放射性体内诊断药物非临床研究技术指导原则》</title><link>https://mp.weixin.qq.com/s/sTn_NGZIP9bqdjPRgNESiA</link><description></description><content:encoded><![CDATA[【速递】CDE发布《放射性体内诊断药物非临床研究技术指导原则》]]></content:encoded><pubDate>Thu, 25 Feb 2021 20:17:46 +0800</pubDate></item></channel></rss>